APO Research
Talk to an analyst

APO RESEARCH · REPORT

Untargeted Metabolomics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Untargeted Metabolomics Market Outlook and Growth Opportunities 2026

3 July 2026192 pages

Choose your research edition.

Industry ResearchUntargeted Metabolomics Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Untargeted Metabolomics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Untargeted Metabolomics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Untargeted Metabolomics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Untargeted Metabolomics Market Analysis and Forecast 2026-2032177 pages · $4,950 USD

Market perspective

The global Untargeted Metabolomics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Untargeted Metabolomics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Untargeted Metabolomics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Untargeted Metabolomics market include Creative Proteomics, Metabolon, Alfa Chemistry, Novelgene Technologies, MtoZ-Biolabs Inc., CD Genomics, Metware Biotechnology Inc (Metware), BGI Genomics and APPLIED PROTEIN TECHNOLOGY, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Untargeted Metabolomics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Untargeted Metabolomics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Untargeted Metabolomics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Untargeted Metabolomics market.

Untargeted Metabolomics Segment by Company

Creative Proteomics

Metabolon

Alfa Chemistry

Novelgene Technologies

MtoZ-Biolabs Inc.

CD Genomics

Metware Biotechnology Inc (Metware)

BGI Genomics

APPLIED PROTEIN TECHNOLOGY

Suzhou PANOMIX Biomedical Tech Co.,Ltd

OBiO Technology ( Shanghai ) Corp.,Ltd.

Beijing Huayi innovation & BioTechnology Co., Ltd

Abace Biotechnology

Metabo-Profile

Untargeted Metabolomics Segment by Type

Plant Untargeted Metabolomics

Human Untargeted Metabolomics

Other

Untargeted Metabolomics Segment by Application

Academic and Research Institutions

Pharmaceutical and Biotechnology Companies

Untargeted Metabolomics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Untargeted Metabolomics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Untargeted Metabolomics key companies, revenue, market share, and recent developments.

3. To split the Untargeted Metabolomics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Untargeted Metabolomics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Untargeted Metabolomics significant trends, drivers, influence factors in global and regions.

6. To analyze Untargeted Metabolomics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Untargeted Metabolomics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Untargeted Metabolomics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Untargeted Metabolomics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Untargeted Metabolomics industry.

Chapter 3: Detailed analysis of Untargeted Metabolomics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Untargeted Metabolomics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Untargeted Metabolomics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Untargeted Metabolomics Industry Trends Table 2. Untargeted Metabolomics Industry Drivers Table 3. Untargeted Metabolomics Industry Opportunities and Challenges Table 4. Untargeted Metabolomics Industry Restraints Table 5. Global Untargeted Metabolomics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Untargeted Metabolomics Revenue Share by Company (2021-2026) Table 7. Global Untargeted Metabolomics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Untargeted Metabolomics Key Company Manufacturing Base & Headquarters Table 9. Global Untargeted Metabolomics Company, Product Type & Application Table 10. Global Untargeted Metabolomics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Untargeted Metabolomics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Plant Untargeted Metabolomics Table 15. Significant Companies of Human Untargeted Metabolomics Table 16. Significant Companies of Other Table 17. Global Untargeted Metabolomics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Untargeted Metabolomics Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Untargeted Metabolomics Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Untargeted Metabolomics Sales Value Share by Type (2021-2026) Table 21. Global Untargeted Metabolomics Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Academic and Research Institutions Table 23. Significant Companies of Pharmaceutical and Biotechnology Companies Table 24. Global Untargeted Metabolomics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Untargeted Metabolomics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Untargeted Metabolomics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Untargeted Metabolomics Sales Value Share by Application (2021-2026) Table 28. Global Untargeted Metabolomics Sales Value Share by Application (2027-2032) Table 29. Global Untargeted Metabolomics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Untargeted Metabolomics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Untargeted Metabolomics Sales Value Share by Region (2021-2026) Table 32. Global Untargeted Metabolomics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Untargeted Metabolomics Sales Value Share by Region (2027-2032) Table 34. Global Untargeted Metabolomics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Untargeted Metabolomics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Untargeted Metabolomics Sales Value Market Share by Country (2021-2026) Table 37. Global Untargeted Metabolomics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Untargeted Metabolomics Sales Value Market Share by Country (2027-2032) Table 39. Creative Proteomics Company Information Table 40. Creative Proteomics Business Overview Table 41. Creative Proteomics Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Creative Proteomics Untargeted Metabolomics Product Portfolio Table 43. Creative Proteomics Recent Development Table 44. Metabolon Company Information Table 45. Metabolon Business Overview Table 46. Metabolon Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Metabolon Untargeted Metabolomics Product Portfolio Table 48. Metabolon Recent Development Table 49. Alfa Chemistry Company Information Table 50. Alfa Chemistry Business Overview Table 51. Alfa Chemistry Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Alfa Chemistry Untargeted Metabolomics Product Portfolio Table 53. Alfa Chemistry Recent Development Table 54. Novelgene Technologies Company Information Table 55. Novelgene Technologies Business Overview Table 56. Novelgene Technologies Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novelgene Technologies Untargeted Metabolomics Product Portfolio Table 58. Novelgene Technologies Recent Development Table 59. MtoZ-Biolabs Inc. Company Information Table 60. MtoZ-Biolabs Inc. Business Overview Table 61. MtoZ-Biolabs Inc. Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio Table 63. MtoZ-Biolabs Inc. Recent Development Table 64. CD Genomics Company Information Table 65. CD Genomics Business Overview Table 66. CD Genomics Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. CD Genomics Untargeted Metabolomics Product Portfolio Table 68. CD Genomics Recent Development Table 69. Metware Biotechnology Inc (Metware) Company Information Table 70. Metware Biotechnology Inc (Metware) Business Overview Table 71. Metware Biotechnology Inc (Metware) Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio Table 73. Metware Biotechnology Inc (Metware) Recent Development Table 74. BGI Genomics Company Information Table 75. BGI Genomics Business Overview Table 76. BGI Genomics Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. BGI Genomics Untargeted Metabolomics Product Portfolio Table 78. BGI Genomics Recent Development Table 79. APPLIED PROTEIN TECHNOLOGY Company Information Table 80. APPLIED PROTEIN TECHNOLOGY Business Overview Table 81. APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio Table 83. APPLIED PROTEIN TECHNOLOGY Recent Development Table 84. Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information Table 85. Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview Table 86. Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio Table 88. Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Development Table 89. OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information Table 90. OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview Table 91. OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio Table 93. OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Development Table 94. Beijing Huayi innovation & BioTechnology Co., Ltd Company Information Table 95. Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview Table 96. Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio Table 98. Beijing Huayi innovation & BioTechnology Co., Ltd Recent Development Table 99. Abace Biotechnology Company Information Table 100. Abace Biotechnology Business Overview Table 101. Abace Biotechnology Untargeted Metabolomics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Abace Biotechnology Untargeted Metabolomics Product Portfolio Table 103. Abace Biotechnology Recent Development Table 104. Metabo-Profile Company Information Table 105. Metabo-Profile Business Overview Table 106. Metabo-Profile Untargeted Metabolomics Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Metabo-Profile Untargeted Metabolomics Product Portfolio Table 108. Metabo-Profile Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Untargeted Metabolomics Product Image Figure 2. Global Untargeted Metabolomics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Untargeted Metabolomics Market Size (2021-2032) & (US$ Million) Figure 4. Global Untargeted Metabolomics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Plant Untargeted Metabolomics Image Figure 8. Human Untargeted Metabolomics Image Figure 9. Other Image Figure 10. Global Untargeted Metabolomics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Untargeted Metabolomics Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Untargeted Metabolomics Sales Value Share by Type (2021-2032) Figure 13. Academic and Research Institutions Image Figure 14. Pharmaceutical and Biotechnology Companies Image Figure 15. Global Untargeted Metabolomics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Untargeted Metabolomics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Untargeted Metabolomics Sales Value Share by Application (2021-2032) Figure 18. Global Untargeted Metabolomics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Untargeted Metabolomics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Untargeted Metabolomics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Untargeted Metabolomics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Untargeted Metabolomics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Untargeted Metabolomics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Untargeted Metabolomics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Untargeted Metabolomics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Untargeted Metabolomics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Untargeted Metabolomics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Untargeted Metabolomics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Untargeted Metabolomics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Untargeted Metabolomics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Plant Untargeted Metabolomics
  • Human Untargeted Metabolomics
  • Other
Applications
  • Academic and Research Institutions
  • Pharmaceutical and Biotechnology Companies
Companies covered
  • Creative Proteomics
  • Metabolon
  • Alfa Chemistry
  • Novelgene Technologies
  • MtoZ-Biolabs Inc.
  • CD Genomics
  • Metware Biotechnology Inc (Metware)
  • BGI Genomics
  • APPLIED PROTEIN TECHNOLOGY
  • Suzhou PANOMIX Biomedical Tech Co.,Ltd
  • OBiO Technology ( Shanghai ) Corp.,Ltd.
  • Beijing Huayi innovation & BioTechnology Co., Ltd
  • Abace Biotechnology
  • Metabo-Profile

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Untargeted Metabolomics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Untargeted Metabolomics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Untargeted Metabolomics Market Dynamics
  1. 2.1 Untargeted Metabolomics Industry Trends
  2. 2.2 Untargeted Metabolomics Industry Drivers
  3. 2.3 Untargeted Metabolomics Industry Opportunities and Challenges
  4. 2.4 Untargeted Metabolomics Industry Restraints
3 Untargeted Metabolomics Market by Company
  1. 3.1 Global Untargeted Metabolomics Company Revenue Ranking in 2025
  2. 3.2 Global Untargeted Metabolomics Revenue by Company (2021-2026)
  3. 3.3 Global Untargeted Metabolomics Company Ranking (2024-2026)
  4. 3.4 Global Untargeted Metabolomics Company Manufacturing Base and Headquarters
  5. 3.5 Global Untargeted Metabolomics Company Product Type and Application
  6. 3.6 Global Untargeted Metabolomics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Untargeted Metabolomics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Untargeted Metabolomics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Untargeted Metabolomics Market by Type
  1. 4.1 Untargeted Metabolomics Type Introduction
  2. 4.1.1 Plant Untargeted Metabolomics
  3. 4.1.2 Human Untargeted Metabolomics
  4. 4.1.3 Other
  5. 4.2 Global Untargeted Metabolomics Sales Value by Type
  6. 4.2.1 Global Untargeted Metabolomics Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Untargeted Metabolomics Sales Value by Type (2021-2032)
  8. 4.2.3 Global Untargeted Metabolomics Sales Value Share by Type (2021-2032)
5 Untargeted Metabolomics Market by Application
  1. 5.1 Untargeted Metabolomics Application Introduction
  2. 5.1.1 Academic and Research Institutions
  3. 5.1.2 Pharmaceutical and Biotechnology Companies
  4. 5.2 Global Untargeted Metabolomics Sales Value by Application
  5. 5.2.1 Global Untargeted Metabolomics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Untargeted Metabolomics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Untargeted Metabolomics Sales Value Share by Application (2021-2032)
6 Untargeted Metabolomics Regional Value Analysis
  1. 6.1 Global Untargeted Metabolomics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Untargeted Metabolomics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Untargeted Metabolomics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Untargeted Metabolomics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Untargeted Metabolomics Sales Value (2021-2032)
  7. 6.3.2 North America Untargeted Metabolomics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Untargeted Metabolomics Sales Value (2021-2032)
  10. 6.4.2 Europe Untargeted Metabolomics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Untargeted Metabolomics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Untargeted Metabolomics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Untargeted Metabolomics Sales Value (2021-2032)
  16. 6.6.2 South America Untargeted Metabolomics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Untargeted Metabolomics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Untargeted Metabolomics Sales Value Share by Country, 2025 VS 2032
7 Untargeted Metabolomics Country-level Value Analysis
  1. 7.1 Global Untargeted Metabolomics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Untargeted Metabolomics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Untargeted Metabolomics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Untargeted Metabolomics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Untargeted Metabolomics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Untargeted Metabolomics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Untargeted Metabolomics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Creative Proteomics
  2. 8.1.1 Creative Proteomics Company Information
  3. 8.1.2 Creative Proteomics Business Overview
  4. 8.1.3 Creative Proteomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Creative Proteomics Untargeted Metabolomics Product Portfolio
  6. 8.1.5 Creative Proteomics Recent Developments
  7. 8.2 Metabolon
  8. 8.2.1 Metabolon Company Information
  9. 8.2.2 Metabolon Business Overview
  10. 8.2.3 Metabolon Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Metabolon Untargeted Metabolomics Product Portfolio
  12. 8.2.5 Metabolon Recent Developments
  13. 8.3 Alfa Chemistry
  14. 8.3.1 Alfa Chemistry Company Information
  15. 8.3.2 Alfa Chemistry Business Overview
  16. 8.3.3 Alfa Chemistry Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Alfa Chemistry Untargeted Metabolomics Product Portfolio
  18. 8.3.5 Alfa Chemistry Recent Developments
  19. 8.4 Novelgene Technologies
  20. 8.4.1 Novelgene Technologies Company Information
  21. 8.4.2 Novelgene Technologies Business Overview
  22. 8.4.3 Novelgene Technologies Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novelgene Technologies Untargeted Metabolomics Product Portfolio
  24. 8.4.5 Novelgene Technologies Recent Developments
  25. 8.5 MtoZ-Biolabs Inc.
  26. 8.5.1 MtoZ-Biolabs Inc. Company Information
  27. 8.5.2 MtoZ-Biolabs Inc. Business Overview
  28. 8.5.3 MtoZ-Biolabs Inc. Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MtoZ-Biolabs Inc. Untargeted Metabolomics Product Portfolio
  30. 8.5.5 MtoZ-Biolabs Inc. Recent Developments
  31. 8.6 CD Genomics
  32. 8.6.1 CD Genomics Company Information
  33. 8.6.2 CD Genomics Business Overview
  34. 8.6.3 CD Genomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CD Genomics Untargeted Metabolomics Product Portfolio
  36. 8.6.5 CD Genomics Recent Developments
  37. 8.7 Metware Biotechnology Inc (Metware)
  38. 8.7.1 Metware Biotechnology Inc (Metware) Company Information
  39. 8.7.2 Metware Biotechnology Inc (Metware) Business Overview
  40. 8.7.3 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Metware Biotechnology Inc (Metware) Untargeted Metabolomics Product Portfolio
  42. 8.7.5 Metware Biotechnology Inc (Metware) Recent Developments
  43. 8.8 BGI Genomics
  44. 8.8.1 BGI Genomics Company Information
  45. 8.8.2 BGI Genomics Business Overview
  46. 8.8.3 BGI Genomics Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BGI Genomics Untargeted Metabolomics Product Portfolio
  48. 8.8.5 BGI Genomics Recent Developments
  49. 8.9 APPLIED PROTEIN TECHNOLOGY
  50. 8.9.1 APPLIED PROTEIN TECHNOLOGY Company Information
  51. 8.9.2 APPLIED PROTEIN TECHNOLOGY Business Overview
  52. 8.9.3 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 APPLIED PROTEIN TECHNOLOGY Untargeted Metabolomics Product Portfolio
  54. 8.9.5 APPLIED PROTEIN TECHNOLOGY Recent Developments
  55. 8.10 Suzhou PANOMIX Biomedical Tech Co.,Ltd
  56. 8.10.1 Suzhou PANOMIX Biomedical Tech Co.,Ltd Company Information
  57. 8.10.2 Suzhou PANOMIX Biomedical Tech Co.,Ltd Business Overview
  58. 8.10.3 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Suzhou PANOMIX Biomedical Tech Co.,Ltd Untargeted Metabolomics Product Portfolio
  60. 8.10.5 Suzhou PANOMIX Biomedical Tech Co.,Ltd Recent Developments
  61. 8.11 OBiO Technology ( Shanghai ) Corp.,Ltd.
  62. 8.11.1 OBiO Technology ( Shanghai ) Corp.,Ltd. Company Information
  63. 8.11.2 OBiO Technology ( Shanghai ) Corp.,Ltd. Business Overview
  64. 8.11.3 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 OBiO Technology ( Shanghai ) Corp.,Ltd. Untargeted Metabolomics Product Portfolio
  66. 8.11.5 OBiO Technology ( Shanghai ) Corp.,Ltd. Recent Developments
  67. 8.12 Beijing Huayi innovation & BioTechnology Co., Ltd
  68. 8.12.1 Beijing Huayi innovation & BioTechnology Co., Ltd Company Information
  69. 8.12.2 Beijing Huayi innovation & BioTechnology Co., Ltd Business Overview
  70. 8.12.3 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Beijing Huayi innovation & BioTechnology Co., Ltd Untargeted Metabolomics Product Portfolio
  72. 8.12.5 Beijing Huayi innovation & BioTechnology Co., Ltd Recent Developments
  73. 8.13 Abace Biotechnology
  74. 8.13.1 Abace Biotechnology Company Information
  75. 8.13.2 Abace Biotechnology Business Overview
  76. 8.13.3 Abace Biotechnology Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abace Biotechnology Untargeted Metabolomics Product Portfolio
  78. 8.13.5 Abace Biotechnology Recent Developments
  79. 8.14 Metabo-Profile
  80. 8.14.1 Metabo-Profile Company Information
  81. 8.14.2 Metabo-Profile Business Overview
  82. 8.14.3 Metabo-Profile Untargeted Metabolomics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Metabo-Profile Untargeted Metabolomics Product Portfolio
  84. 8.14.5 Metabo-Profile Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst